GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Paratek Pharmaceuticals Inc (FRA:N4CN) » Definitions » Net Margin %

Paratek Pharmaceuticals (FRA:N4CN) Net Margin % : -38.23% (As of Jun. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Paratek Pharmaceuticals Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Paratek Pharmaceuticals's Net Income for the three months ended in Jun. 2023 was €-13.4 Mil. Paratek Pharmaceuticals's Revenue for the three months ended in Jun. 2023 was €35.1 Mil. Therefore, Paratek Pharmaceuticals's net margin for the quarter that ended in Jun. 2023 was -38.23%.

The historical rank and industry rank for Paratek Pharmaceuticals's Net Margin % or its related term are showing as below:

FRA:N4CN' s Net Margin % Range Over the Past 10 Years
Min: -391966.67   Med: -656.39   Max: -37.77
Current: -37.77


FRA:N4CN's Net Margin % is not ranked
in the Biotechnology industry.
Industry Median: -148.41 vs FRA:N4CN: -37.77

Paratek Pharmaceuticals Net Margin % Historical Data

The historical data trend for Paratek Pharmaceuticals's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Paratek Pharmaceuticals Net Margin % Chart

Paratek Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -656.39 -778.45 -221.85 -48.85 -42.16

Paratek Pharmaceuticals Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -63.94 -74.99 -9.85 -68.97 -38.23

Competitive Comparison of Paratek Pharmaceuticals's Net Margin %

For the Biotechnology subindustry, Paratek Pharmaceuticals's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Paratek Pharmaceuticals's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Paratek Pharmaceuticals's Net Margin % distribution charts can be found below:

* The bar in red indicates where Paratek Pharmaceuticals's Net Margin % falls into.



Paratek Pharmaceuticals Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Paratek Pharmaceuticals's Net Margin for the fiscal year that ended in Dec. 2022 is calculated as

Net Margin=Net Income (A: Dec. 2022 )/Revenue (A: Dec. 2022 )
=-60.006/142.344
=-42.16 %

Paratek Pharmaceuticals's Net Margin for the quarter that ended in Jun. 2023 is calculated as

Net Margin=Net Income (Q: Jun. 2023 )/Revenue (Q: Jun. 2023 )
=-13.432/35.131
=-38.23 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Paratek Pharmaceuticals  (FRA:N4CN) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Paratek Pharmaceuticals Net Margin % Related Terms

Thank you for viewing the detailed overview of Paratek Pharmaceuticals's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Paratek Pharmaceuticals (FRA:N4CN) Business Description

Traded in Other Exchanges
N/A
Address
75 Park Plaza, 4th Floor, Boston, MA, USA, 02116
Paratek Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's medical research is based on tetracycline chemistry and biology to create two antibacterials: omadacycline and sarecycline. NUZYRA (Omadacycline) is an antibacterial for skin infections and treatment of community-acquired bacterial pneumonia. SEYSARA (Sarecycline) is designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals is also involved in research to treat multiple sclerosis, spinal muscular atrophy, and systemic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel diseases.

Paratek Pharmaceuticals (FRA:N4CN) Headlines

No Headlines